Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 1

2(25.0%)

Phase 2

1(12.5%)

N/A

1(12.5%)

8Total

Phase 3(4)

Phase 1(2)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07561034Not ApplicableNot Yet Recruiting

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

Role: collaborator

NCT04691154Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Role: lead

NCT06129240Active Not Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Role: lead

NCT07285655Phase 3Not Yet Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Role: lead

NCT03992755Phase 3Active Not Recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Role: lead

NCT03399604Phase 3Completed

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Role: lead

NCT03884465Phase 2Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Role: lead

NCT02982889Phase 1Completed

Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations

Role: lead

NCT01224262Phase 1Completed

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

Role: lead

All 9 trials loaded